The prognostic value of systemic inflammatory response index (SIRI) in acute coronary syndrome patients treated with primary percutaneous coronary intervention: a meta-analysis and systematic review
A meta-analysis evaluates SIRI's impact on mortality and cardiovascular outcomes in ACS patients after PCI, suggesting its clinical utility.
Key Points
This research aims to assess the prognostic significance of the systemic inflammatory response index (SIRI) in patients with acute coronary syndrome (ACS) after undergoing primary percutaneous coronary intervention (pPCI).
Conducted systematic searches in PubMed, Embase, and The Cochrane Library up to June 2025.
Included studies were focused on SIRI and its role in ACS patients post-pPCI.
Outcomes measured included all-cause mortality and major adverse cardiovascular events (MACE).
Elevated SIRI significantly predicted all-cause mortality (OR 3.32; 95% CI 1.29 to 8.54; p = 0.01).
High SIRI levels were linked to increased MACE (OR 2.45; 95% CI 1.74 to 3.45; p = 0.001).
SIRI indicated a significant risk for new-onset acute myocardial infarction (OR 1.86; 95% CI 1.25 to 2.77; p = 0.001).
SIRI was also associated with higher rates of myocardial revascularization (OR 1.64; 95% CI 1.35 to 1.98; p = 0.001).